Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

The purpose of this study is to evaluate the efficacy and safety of venetoclax combined with azacitidine regimen for newly diagnosed T-ALL patients.

Trial Details

NCT ID
NCT05376111
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Soochow University
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • Venetoclax, Azacitidine
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Patients aged ≥ 15.
  • Patients diagnosed with T-ALL according to 2016 WHO criteria for precursor lymphoid neoplasms.
  • ECOG performance status score less than 3.
  • Patients without serious heart, lung, liver, or kidney dysfunction.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →